R&D channel feed – Endpoints News

R&D channel feed

GSK’s Nucala cuts exacerbations in Phase 3 COPD trial, but numbers remain under wraps

8 months ago

Lilly unveils more positive late-stage data for its once-weekly insulin

8 months ago

IN8bio pauses glioblastoma program, halves workforce as it prioritizes leukemia asset

8 months ago

Higher dose of Spinraza helped spinal muscular atrophy patients, Biogen says

8 months ago

Moderna’s mpox vaccine outperforms approved version in preclinical study

8 months ago

Transplant biotech eGenesis snags $191M after first use of gene-edited pig kidney

9 months ago

Roche unveils more mid-stage data for BTK inhibitor in relapsing multiple sclerosis

9 months ago

Cell therapy startup ArsenalBio raises $325M as it runs early solid tumor trials

9 months ago

Athira’s small molecule drug for Alzheimer’s fails in mid-stage study

9 months ago

BioAge files for IPO, riding momentum for weight loss drugs

9 months ago

Researchers seek answers as they spell out Phase 3 failure of Bayer’s next-gen anticoagulant

9 months ago

Three Dyne executives leave as company reports new Duchenne drug data

9 months ago

Praxis' epilepsy drug reduces seizures by 46% in pediatric patients in Phase 2 study

9 months ago

ProKidney axes one Phase 3 study, aims for 'expedited approval pathway' using another

9 months ago

With few specifics, Recursion underwhelms with first Phase 2 readout, but ‘plans to advance’ drug

9 months ago

Updated: Vaxcyte surges on Phase 1/2 data for 31-valent pneumococcal vaccine

9 months ago

Exclusive: Duke spinout launches in hopes of prevailing with brain cancer bispecific where Amgen, Roche did not

9 months ago

Arrowhead spotlights key pancreatitis figures from Phase 3 lipid disease study to differentiate itself from Ionis

9 months ago

Sanofi’s BTK inhibitor goes 1-for-3 in key MS trials, slows disability progression

9 months ago

Bayer’s Kerendia cuts heart death, failure and hospitalization by 16% in Phase 3 trial

9 months ago

Merck opens London lab as it makes push into immunology and the UK

9 months ago

Novo offers detailed look at semaglutide’s cardiac outcomes in Phase 3 trial as it tees up resubmission

9 months ago

NuCana stops Phase 2 as chemotherapy derivative 'unlikely' to meet primary endpoint

9 months ago

Updated: Alnylam’s new Phase 3 ATTR data bring uncertainty to standard of care ambitions

9 months ago

First page Previous page 29 30 313233 34 35 Next page Last page